Results 111 to 120 of about 12,625 (176)

Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study. [PDF]

Virol J
Prager M, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, Valipour A, Zoufaly A, Wenisch C, Haider D, Burgmann H, Thalhammer F, Götzinger F, Jilma B, Karnthaler U, Zeitlinger M, Jorda A.   +16 more
europepmc   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Effectiveness of Antivirals Nirmatrelvir-Ritonavir and Molnupiravir in Viral Sepsis: Retrospective Cohort Study. [PDF]

JMIR Public Health Surveill
Lee TTL, Lyu AC, Jiang TT, Chan SCL, Chan CY, Yip ETF, Luk LYF, Ho JWK, So KWL, Tsui OWK, Lam ML, Lee SY, Yamamoto T, Tong CK, Wong MS, Wong ELY, Wai AKC, Rainer TH.   +17 more
europepmc   +1 more source

Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients. [PDF]

Eur J Clin Microbiol Infect Dis
de Arpe CF, Homen R, Valls-Carbó A, Barrado J, Olmos-Mata C, Pérez-Somarriba J, Muñoz-Gomez A, Núñez-Orantos MJ, Cabello-Clotet N, Estrada V.   +9 more
europepmc   +1 more source

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source

Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. [PDF]

Ther Adv Pulm Crit Care Med
Jehle DVK, Sunesra R, Williams SM, Bilby NJ, Paul KK, Hill K.   +5 more
europepmc   +1 more source

Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial. [PDF]

Health Qual Life Outcomes
Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC.   +4 more
europepmc   +1 more source

Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System. [PDF]

Open Forum Infect Dis
Bui DP, Hynes DM, Wong E, Vergun R, Yan L, Li Y, Rajeevan N, Berry K, Lin HM, Huang Y, Govier DJ, Aslan M, Ioannou G, Bajema KL.   +13 more
europepmc   +1 more source

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. [PDF]

Trials
Blomberg B, Myklebust NN, Oppegaard O, Tøndel C, Cox RJ, Iversen A, Lehmann ME, Sandvig A, Dahl TB, Valderhaug VD, Szodoray P, Wilhelmsen M, Kirsebom BE, Glambek M, Kaarbøe O, Aukrust P, Lie RT, Langeland N.   +17 more
europepmc   +1 more source